Stock Price Forecast

Dec. 5, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading ContraFect Corp chart...

About the Company

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba

CEO

Roger Pomerantz

Exchange

OTC MARKETS

Website

https://www.contrafect.com/

$M

Total Revenue

33

Employees

$1M

Market Capitalization

-0.01

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CFRX News

ContraFect files patent for antibacterial lysin-amp polypeptide constructs and compositions

12d ago, source: Pharmaceutical Technology

Discover how ContraFect Corp.'s patent on lysin-AMP polypeptide constructs revolutionizes antibacterial therapies. Learn about isolated lysin polypeptides and methods for treating Gram-negative ...

We don't have any news on ContraFect Corp at the moment.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...